Clinical Trials Logo

Tachycardia, Ventricular clinical trials

View clinical trials related to Tachycardia, Ventricular.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05820035 Active, not recruiting - Clinical trials for Paroxysmal Supraventricular Tachycardia

A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia

PSVT
Start date: March 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to explore the safety and efficacy of a Pulsed Field Ablation(PFA) Device and Force Sensing Pulsed Field Ablation Catheter in the treatment of Paroxysmal Supraventricular Tachycardia(PSVT)

NCT ID: NCT05225935 Active, not recruiting - Clinical trials for Ventricular Tachycardia

Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia

InEurHeart
Start date: June 29, 2022
Phase: N/A
Study type: Interventional

This double arm randomized study will compare 2 ventricular tachycardia ablation strategies: the standard strategy based on invasive substrate and VT mapping with 3D electro-anatomical system vs a tailored strategy which identifies targets based on pre-procedural CT-scan imaging. The primary endpoint will be procedure duration and secondary endpoints will include safety and efficacy criteria as well as medico-economic evaluation.

NCT ID: NCT04895540 Active, not recruiting - Clinical trials for Ventricular Tachycardia

South Asian Arrhythmogenic Cardiomyopathy Registry

Start date: April 10, 2021
Phase:
Study type: Observational [Patient Registry]

Arrhythmogenic Cardiomyopathy (ACM) is increasingly identified as an important cause of cardiac morbidity and mortality, especially of SCD, in a younger population. Although there are no epidemiological data available, the investigators' experience is that in the North Indian region, ACM is rare outside our regions. ACM is also an understudied cardiac disorder in the South-Asian region. An ethnic nonmigratory population inhabits the two regions, and consanguineous marriages are common. Based on these observations, the investigators firmly believe that there may be a founder gene in our populations responsible for the increased incidence of ACM. Our project includes a thorough phenotypic analysis ((ECG, Holter, and echocardiography) in the ACM patients and their first-degree relatives; cardiac MRI and high resolution endocardial bipolar and unipolar voltage mapping (using HD grid catheter) in the patients. The patient provided blood for the extraction of DNA will first undergo target panel sequencing for 20 known classic right-dominant ACM and left-dominant ACM. If this is negative for known pathogenic and likely pathogenic variants but identified novel variants of uncertain significance (VUS), then co-segregation analysis in family members will be performed. This technique can provide helpful information to reclassify VUSs. If both these are negative, then whole-exome 'trio' analysis will be performed, whch includes the proband and two family members, to triangulate from all 20,000 genes to a list of candidates for further interrogation. The investigators wish to provide comprehensive answers to the research question by combining the genetic analysis with phenotypic evaluation.

NCT ID: NCT04893317 Active, not recruiting - Clinical trials for Monomorphic Ventricular Tachycardia

Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)

CryoCure-VT
Start date: May 26, 2021
Phase: N/A
Study type: Interventional

A prospective, single-arm, multi-center, pre-market, clinical study designed to provide safety and performance data regarding the use of the Adagio Medical VT Cryoablation System in the treatment of ventricular tachycardia.

NCT ID: NCT04798768 Active, not recruiting - Clinical trials for Tachycardia, Ventricular

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

MODULAR ATP
Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

NCT ID: NCT04765943 Active, not recruiting - Clinical trials for Myocardial Infarction

Prognosis Impact of NSVTs After an AMI (TeVeO Study).

TeVeO
Start date: August 15, 2020
Phase:
Study type: Observational

Nowadays, Sudden Cardiac Death (SCD) due to malignant arrhythmias is an important cause of death among acute myocardial infarction (AMI) survivors. Preventive strategies with implantable cardioverter-defibrillators (ICD) are the best clinical option for patients, but associated sociosanitary impact in the National Health Systems and the fact that current implant strategy not always results in benefits for the patient requires to develop further selection criteria. The TeVeO project aims to study the events that take place early following an AMI to predict the short- and long-term risk of experiencing a potentially lethal ventricular tachycardia (VT). The project will carry out an observational and multicentric study involving 5 different hospitals to: a) qualitative and quantitative characterize non-sustained VTs (NSVT) that take place during the first 6 months after an AMI and b) characterize the evolution of the substrate (scar and surrounding tissue) in patients meeting criteria for ICD implant. Patients included in the study will be implanted with an implantable loop recorder (ILR) in order to register NSVT and cMRI images will be acquired prior to hospital discharge and at 6 months after AMI to study the substrate. Further patients' management will follow the protocols within each entity. Project results will allow us to stratify patients according to identified risks for developing malignant VT, which will improve patient selection for ICD implantation and will contribute to tailor patients' treatment and prevention, improving the cost-effectiveness of these devices and minimizing their associated problems and sociosanitary burden.

NCT ID: NCT04134845 Active, not recruiting - Clinical trials for Ventricular Tachycardia

A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

Start date: August 21, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, placebo controlled trial of Dantrolene (N= 84 participants) to demonstrate the feasibility of using I.V. dantrolene to study the effect of RyR2 inhibition on cardiac electrophysiology, hemodynamics and ventricular arrhythmia inducibility in patients with structural heart disease referred for VT ablation. The investigators will also explore the pharmacokinetic/pharmacodynamic relationship of I.V. dantrolene and it short-term effect on specific cardiac electrophysiologic and hemodynamic parameters.

NCT ID: NCT04004624 Active, not recruiting - Clinical trials for Ventricular Tachycardia

Physiologically Guided VT Ablation

Start date: October 12, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy of VT ablation guided by functional evaluation of the substrate to specifically target the reentry-vulnerable zones in patients with infarct-related VT.

NCT ID: NCT03867747 Active, not recruiting - Clinical trials for Ventricular Tachycardia

Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

RAVENTA
Start date: December 2, 2019
Phase: N/A
Study type: Interventional

Patients with refractory ventricular extrasystoles or tachycardia not eligible for catheter ablation will receive single fraction stereotactic body radiation therapy (cardiac radiosurgery) with 25 Gy. Investigators initiated this study to demonstrate that in at least 70% of the patients the planned cardiac radiosurgery may be performed without any interruption or treatment related interventional events within the first 30 days after treatment.

NCT ID: NCT03649022 Active, not recruiting - Clinical trials for Ventricular Tachycardia

"Ventricular Tachycardia Ablation Registry".

Start date: July 25, 2017
Phase:
Study type: Observational [Patient Registry]

Catheter ablation of Ventricular Tachycardias is a well-established approach in clinical practice in patients with Implantable Cardioverter Defibrillator (ICD) implanted. Previous studies have shown a significant reduction in appropriate shocks (~ 20%) and a significant reduction in hospitalizations for cardiovascular reasons (~ 12%) in patients with ischemic heart disease treated with ablation. Recent works have also shown the effectiveness of the ablation procedure using as procedural target the reduction of late potentials. However, actually it is necessary to have an homogenize and accepted mapping scheme in Sinus Rhythm to ablate Ventricular Tachycardias related to scar substrate in patients with: - Previous MI - Previous myocarditis - Arrhythmogenic Right Ventricular Dysplasia (ARVD) - Idiopathic Dilated Cardiomyopathy (IDCM) Scope of the registry is to collect data during cardiac mapping in Sinus Rhythm in patients indicated for Ventricular Tachycardia ablation, that will be performed per clinical practice, by using the St. Jude Medical EnSiteTM PrecisionTM mapping system. The objective of the present registry is: to assess the acute and long-term efficacy of the strategy of substrate abolition (abolishment of complex and late potentials) guided by electroanatomic mapping with Precision software.